Biology of Blood and Marrow Transplantation · 2013 · 39 citations · 22 references
PharmacyPharmacokineticsPharmacologyChemotherapyImmunopharmacologyPharmacokinetic VariabilityChemotherapy In Hematologic MalignanciesHematologic ToxicityHematopoietic Stem Cell Transplant PharmacotherapyPharmacokinetics Of ImmunotherapiesTargeted Therapy PharmacokineticsToxicity ManagementArea Under The Concentration - Time CurveArea Under The Plasma Concentration-time CurveBusulfan PharmacokineticsChemotherapy Dose-limiting ToxicityChemotherapy Regimen DesignConcentration-time Curve CharacterizationDrug Toxicity After TransplantationTransplantation For Hematologic Malignancies
A combination of fludarabine (Flu) and daily i.v. busulfan (Bu) is well tolerated and effective in patients undergoing allogeneic hematopoietic stem cell transplantation. Although there is some evidence that Bu exposures exceeding 6000 μM.min [corrected] may lead to excessive toxicity, there is little information on the effect of exposures below this level on outcomes. We studied Bu exposure, as measured by area under the concentration-time curve (AUC), in 158 patients with various hematologic malignancies in an attempt to identify an optimal range for targeted therapy. The preparative chemotherapy regimen comprised Flu 50 mg/m(2) on days -6 to -2 and i.v. Bu 3.2 mg/kg on days -5 to -2 inclusive. Graft-versus-host disease (GVHD) prophylaxis included methotrexate, cyclosporin A, and antithymocyte globulin. Patients with Bu exposures below the median AUC of 4439 μM.min [corrected] were at increased risk for acute GVHD grade II-IV (hazard ratio [HR], 2.30; 95% confidence interval [CI], 1.19 to 4.49; P = .014). Those in the highest and lowest Bu exposure quartiles (daily AUC <3814 μM.min and >4993 μM.min) [corrected] had an increased risk of nonrelapse mortality (subdistribution HR, 3.32; 95% CI, 1.46 to 7.54; P = .004), as well as worse disease-free survival (HR, 1.81; 95% CI, 1.09 to 2.99; P = .021) and overall survival (HR, 1.94; 95% CI, 1.12 to 3.37; P = .018). Bu exposures between 4440 and 4993 μM/min were accompanied by the lowest risk of both nonrelapse mortality and acute GVHD.
22
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Warren D. Shlomchik, Matthew S. Couzens, Cheng Bi Tang et al. · Science · 1999 · 1.2K citations
Marcos de Lima, Daniel R. Couriel, Peter F. Thall et al. · Blood · 2004 · 422 citations